| 1 | in a clinical trial | | | | | | | 3 | 0.28% |
| 2 | female sexual arousal disorder | | | | | | | 3 | 0.28% |
| 3 | important in clinical trials? | | | | | | | 2 | 0.18% |
| 4 | informed and how is | | | | | | | 2 | 0.18% |
| 5 | and how is patient | | | | | | | 2 | 0.18% |
| 6 | knowledge and improve patient | | | | | | | 2 | 0.18% |
| 7 | and improve patient care | | | | | | | 2 | 0.18% |
| 8 | you are free to | | | | | | | 2 | 0.18% |
| 9 | to continue the study | | | | | | | 2 | 0.18% |
| 10 | discuss the protocol with | | | | | | | 2 | 0.18% |
| 11 | participating in clinical trials | | | | | | | 2 | 0.18% |
| 12 | irritable bowel syndrome diarrhea | | | | | | | 2 | 0.18% |
| 13 | current trials about us | | | | | | | 2 | 0.18% |
| 14 | trials irritable bowel syndrome | | | | | | | 2 | 0.18% |
| 15 | adult trials irritable bowel | | | | | | | 2 | 0.18% |
| 16 | excluding participants with high | | | | | | | 1 | 0.09% |
| 17 | participants with high blood | | | | | | | 1 | 0.09% |
| 18 | with high blood pressure | | | | | | | 1 | 0.09% |
| 19 | high blood pressure or | | | | | | | 1 | 0.09% |
| 20 | blood pressure or other | | | | | | | 1 | 0.09% |
| 21 | pressure or other comorbidities | | | | | | | 1 | 0.09% |
| 22 | skip to content cardiovascular | | | | | | | 1 | 0.09% |
| 23 | end up excluding many | | | | | | | 1 | 0.09% |
| 24 | may end up excluding | | | | | | | 1 | 0.09% |
| 25 | for example a clinical | | | | | | | 1 | 0.09% |
| 26 | up excluding many people | | | | | | | 1 | 0.09% |
| 27 | excluding many people over | | | | | | | 1 | 0.09% |
| 28 | many people over 65 | | | | | | | 1 | 0.09% |
| 29 | people over 65 years | | | | | | | 1 | 0.09% |
| 30 | over 65 years old | | | | | | | 1 | 0.09% |
| 31 | 65 years old who | | | | | | | 1 | 0.09% |
| 32 | years old who are | | | | | | | 1 | 0.09% |
| 33 | old who are more | | | | | | | 1 | 0.09% |
| 34 | who are more likely | | | | | | | 1 | 0.09% |
| 35 | example a clinical trial | | | | | | | 1 | 0.09% |
| 36 | are applicable to all | | | | | | | 1 | 0.09% |
| 37 | groups for example a | | | | | | | 1 | 0.09% |
| 38 | carefully consider the inclusion | | | | | | | 1 | 0.09% |
| 39 | risk optimal treatment responses | | | | | | | 1 | 0.09% |
| 40 | and the development of | | | | | | | 1 | 0.09% |